Drugs in development for toxoplasmosis: advances, challenges, and current status

PH Alday, JS Doggett - Drug design, development and therapy, 2017 - Taylor & Francis
Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are
currently used to treat toxoplasmosis commonly have toxic side effects and require …

Human toxoplasmosis–Searching for novel chemotherapeutics

M Antczak, K Dzitko, H Długońska - Biomedicine & Pharmacotherapy, 2016 - Elsevier
The protozoan Toxoplasma gondii, an obligate intracellular parasite, is an etiological agent
of human and animal toxoplasmosis. Treatment regimens for T. gondii-infected patients …

[图书][B] Neosporosis in animals

JP Dubey, A Hemphill, R Calero-Bernal, G Schares - 2017 - taylorfrancis.com
Key features: Written by the scientist who named this parasite and was the first to set up
proper diagnostic techniques Serves as the first ever book to provide information on the …

Toxoplasmosis: Current and emerging parasite druggable targets

RE Hajj, L Tawk, S Itani, M Hamie, J Ezzeddine… - Microorganisms, 2021 - mdpi.com
Toxoplasmosis is a prevalent disease affecting a wide range of hosts including
approximately one-third of the human population. It is caused by the sporozoan parasite …

Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity

M Silva, C Teixeira, P Gomes, M Borges - Microorganisms, 2021 - mdpi.com
Toxoplasmosis is a parasitic disease caused by the globally distributed protozoan parasite
Toxoplasma gondii, which infects around one-third of the world population. This disease …

Toxoplasma gondii infection: novel emerging therapeutic targets

J Müller, A Hemphill - Expert opinion on therapeutic targets, 2023 - Taylor & Francis
Introduction Toxoplasmosis constitutes a challenge for public health, animal production, and
welfare. So far, only a limited panel of drugs has been marketed for clinical applications. In …

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal …

RSR Vidadala, KL Rivas, KK Ojo… - Journal of medicinal …, 2016 - ACS Publications
New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by
the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent …

An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii

R Sánchez-Sánchez, D Imhof, YP Hecker… - The Journal of …, 2024 - academic.oup.com
Congenital toxoplasmosis in humans and in other mammalian species, such as small
ruminants, is a well-known cause of abortion and fetal malformations. The calcium …

Treatment of toxoplasmosis and neosporosis in farm ruminants: state of knowledge and future trends

R Sánchez-Sánchez, P Vázquez, I Ferre… - Current topics in …, 2018 - ingentaconnect.com
Toxoplasmosis and neosporosis are closely related protozoan diseases that lead to
important economic impacts in farm ruminants. Toxoplasma gondii infection mainly causes …

Analysis of CDPK1 targets identifies a trafficking adaptor complex that regulates microneme exocytosis in Toxoplasma

AW Chan, M Broncel, E Yifrach, NR Haseley… - Elife, 2023 - elifesciences.org
Apicomplexan parasites use Ca 2+-regulated exocytosis to secrete essential virulence
factors from specialized organelles called micronemes. Ca 2+-dependent protein kinases …